- patients in oms progression class 9 - patients with exclusion criteria to the corimuno-19 cohort - pregnancy - active cancer with ongoing treatment - acute use of niv for copd exacerbation or cardiac decompensation associated to covid-19 - oxygen patient requiring long-term oxygen before hospitalization - patient already included in an interventional research - risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery during the last 3 weeks - hypersensitivity to the active substance (bevacizumab) or to any of the excipients (sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide, water for injection - hypersensitivity to chinese hamster ovary (cho) cell products or other recombinant human or humanised antibodies - persistant uncontrolled arterial hypertension after using to anti-hypertensive drugs - current documented bacterial infection not controlled by antibiotics. - active viral diseases (especially active herpes, chickenpox, shingles), - active tuberculosis or disseminated strongyloidiasis - patient with known active hepatitis or with increased level of sgot or sgpt ≥5n - patient with anormal laboratory results: absolute neutrophil count (anc) ≤ 1.0 x 109/l, platelets (plt) < 50 g /l

- patients in oms progression class 9 - patients with exclusion criteria to the corimuno-19 cohort - pregnancy - active cancer with ongoing treatment - acute use of niv for copd exacerbation or cardiac decompensation associated to covid-19 - oxygen patient requiring long-term oxygen before hospitalization - patient already included in an interventional research - risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery during the last 3 weeks - hypersensitivity to the active substance (bevacizumab) or to any of the excipients (sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide, water for injection - hypersensitivity to chinese hamster ovary (cho) cell products or other recombinant human or humanised antibodies - persistant uncontrolled arterial hypertension after using to anti-hypertensive drugs - current documented bacterial infection not controlled by antibiotics. - active viral diseases (especially active herpes, chickenpox, shingles), - active tuberculosis or disseminated strongyloidiasis - patient with known active hepatitis or with increased level of sgot or sgpt ≥5n - patient with anormal laboratory results: absolute neutrophil count (anc) ≤ 1.0 x 109/l, platelets (plt) < 50 g /l

- patients in oms progression class 9 - patients with exclusion criteria to the corimuno-19 cohort - pregnancy - active cancer with ongoing treatment - acute use of niv for copd exacerbation or cardiac decompensation associated to covid-19 - oxygen patient requiring long-term oxygen before hospitalization - patient already included in an interventional research - risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery during the last 3 weeks - hypersensitivity to the active substance (bevacizumab) or to any of the excipients (sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide, water for injection - hypersensitivity to chinese hamster ovary (cho) cell products or other recombinant human or humanised antibodies - persistant uncontrolled arterial hypertension after using to anti-hypertensive drugs

- patients in oms progression class 9 - patients with exclusion criteria to the corimuno-19 cohort - pregnancy - active cancer with ongoing treatment - acute use of niv for copd exacerbation or cardiac decompensation associated to covid-19 - oxygen patient requiring long-term oxygen before hospitalization - patient already included in an interventional research - risk of bleeding especially hemoptysis, active venous or arterial thromboembolic disease and recent surgery during the last 3 weeks - hypersensitivity to the active substance (bevacizumab) or to any of the excipients (sucrose, succinic acid, disodium edetate, polysorbate 80, sodium hydroxide, water for injection - hypersensitivity to chinese hamster ovary (cho) cell products or other recombinant human or humanised antibodies - persistant uncontrolled arterial hypertension after using to anti-hypertensive drugs